BRAF, HRAS, KRAS, NRAS and CDKN2A genes analysis in cultured melanocytes used for vitiligo treatment

International Journal of Dermatology

Volumn 50, Issue 2, 2011, Pages 180-183

  Czajkowski, Rafal ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; RAF PROTEIN; RAS PROTEIN;

ADULT; ARTICLE; BRAF GENE; CDKN2A GENE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL TRANSPLANTATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC DAMAGE; HUMAN; HUMAN CELL; MALE; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOGENESIS; MELANOMA; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; VITILIGO;

ADULT; CELL CULTURE TECHNIQUES; CELLS, CULTURED; EXONS; FEMALE; HUMANS; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; TETRADECANOYLPHORBOL ACETATE; VITILIGO; YOUNG ADULT;

EID: 78751615425     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04675.x     Document Type: Article

References (15)

1. Czajkowski R. Comparison of melanocytes transplantation methods for the treatment of vitiligo. Dermatol Surg 2004; 30: 1400-1405.
2. Krasagakis K, Garbe C, Kruger-Krasagakes S, et al. 12-O-Tetradecanoylphorbol-13-acetate not only modulates proliferation rates, but also alters antigen expression and LAK-cell susceptibility of normal human melanocytes in vitro. J Invest Dermatol 1993; 100: 653-659.
3. Nageatte I, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol Mech Dis 2009; 4: 551-579.
4. Lerner AB, Halaban R, Klaus SN, et al. Transplantation of human melanocytes. J Invest Dermatol 1987; 89: 219-224.
5. Eisinger M, Marko O. Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci USA 1982; 79: 2018-2022.
6. Rummel MM, Sers C, Johnson JP. Phorbol ester and cyclic AMP-mediated regulation of the melanoma-associated cell adhesion molecule MUC18/MCAM. Cancer Res 1996; 56: 2218-2223.
7. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003; 22: 3092-3098.
8. Czajkowski R, Drewa T, Woźniak A, et al. Cell cycle in sporadic melanoma. Int J Dermatol 2002; 41: 550-556.
9. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19-20.
10. Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006; 16: 267-273.
11. Tsao H, Zhang X, Fowlkes K, et al. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000; 60: 1800-1804.
12. Albino AP, Fountain JW. Molecular genetics of malignant melanoma. In: Nathanson L, ed. Current Research and Clinical Management of Melanoma. Norwell, MA: Kluwer Academic, 1993: 201-255.
13. Demunter A, Stas M, Degreef H, et al. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol 2001; 117: 1483-1489.
14. Reifenberger J, Knobbe CB, Sterzinger AA, et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004; 109: 377-384.
15. Shukla VK, Hughes DC, Hughes LE, et al. Ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res 1989; 5: 121-127.